Personalized diagnostics Theranostics Health specializes in proteomics-based diagnostics and translational research from preclinical studies to Phase II trials, enabling drug developers to tailor targeted therapies based on tumor proteomes and signaling pathways.

Clinical test services As a CAP-CLIA laboratory service provider, the company offers clinically actionable assays such as TheraLink HER Family, enabling physicians to align treatments with patient-specific biomarker profiles, presenting a direct pathway for revenue through diagnostic testing.

Targeted therapy focus With capabilities to assess phospho-activation and downstream signaling in EGFR, HER2, and HER3 across primary and metastatic breast cancers, there are clear opportunities to partner with pharma firms developing molecular targeted therapies.

Strategic partnerships Historically operating as an independent unit and later acquired by Avant Diagnostics, there may be collaborative or integration opportunities with broader oncology diagnostic platforms and CRO/biotech pipelines seeking niche proteomics assays.

Growth readiness Revenue in the low-to-mid seven-figure range suggests a scalable service model with potential upsell to expanded RPMA panels, additional biomarkers, and broader cancer indications as client pipelines expand.